Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10008 of 10107  at  6/18/2019 10:05:54 AM  by

biochemyst


 In response to msg 10007 by  Aspector
view thread

Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA

 I see zero chance for PCSK9 mabs once MDCO's RNAi-based inhibitor is approved. Mabs are massively expensive, require IV administration, and have poor PD (redone every couple weeks).  
 
It may be the case that lowering triglycerides is the 1-2 punch that results in such a massive lowering if cardiovascular disease we start calling these drugs the "heart-attack vaccines"
 
Of course Amgen could buy just that drug, but it's clear they love the whole sand box.  They seem to be spending vast time and resources investigating RNAi, so why not bolt it on when you're sure it's ready? 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 7     Views: 279
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10010 Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA jetmanbash 0 6/18/2019 8:51:42 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...